Risk of Uncomplicated Peptic Ulcer in the General Population

NCT01888588 COMPLETED

The analyses are conducted in a previous population-based cohort study using The Health Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses are: To estimate the relative risk of uncomplicated symptomatic peptic ulcer (UPU) associated with use of low dose aspirin (ASA) and other anti-inflammatory drugs (NSAIDs, steroids) in the general population To estimate the dose-response and duration-response associated with use of these drugs To estimate the relative risk of UPU associated with naive/non-naive use of low dose ASA in the general population To evaluate the effect of proton pump inhibitors (PPI) (alone or in combination with anti-inflammatory drugs) on the occurrence of UPU in the general population To investigate the management of low dose ASA/oral antiplatelets after UPU

Details

Lead sponsor	AstraZeneca
Status	COMPLETED
Enrolment	4000
Start date	2012-09
Completion	2013-05

Conditions

• Peptic Ulcer [Iowa Type (107680.0010)]

Interventions

• Risk of symptomatic peptic ulcer

Primary outcomes

• Relative risk (ratio) of uncomplicated peptic ulcer (UPU) associated with low dose ASA, other antiinflammatory drugs and other common drugs for chronic diseases(paracetamol, SSRI, tricyclic antidepressants, anticoagulants, acid suppressing drugs) — From Januar 1 1997 till December 31 2005, an expected average of 4 years.
  Relative risk (ratio) of UPU associated with current use of the different types of drugs versus non-use.
• Management of aspirin after uncomplicated peptic ulcer (UPU). — From January 1, 1997 till december 31, 2005, an average of 4 years

Countries

Spain